BIA reaction to the 2019 general election result


Steve Bates OBE, Chief Executive of the BIA said “A Conservative majority offers a new era of political stability at Westminster, which makes long term business decision making simpler for our sector. 

“We look forward to working with the new Government on implementing their manifesto pledges, including the creation of the Innovative Medicines Fund, expanding R&D tax credits, and fulfilling the Prime Minister’s personal pledge of the ‘fastest ever increase’ in R&D spending.

“The UK life sciences sector is a key global cluster and is well set to thrive in the coming years. It is a core and growing part of the UK’s science based innovation economy delivering high quality jobs and growth. 

“Our key priorities are ensuring companies can continue to access the capital and talent they need, working in partnership to deliver the life sciences strategy and ensuring NHS patients continue to access the latest innovative medicines.

On Brexit

“The immediate way forward on the withdrawal agreement is now clear, and industry’s hard work over the last few years to ensure the political declaration enables the possibility of continued close co-operation on medicines regulation and science and innovation, is recognised and now frames key parts of the coming negotiations.”


Notes to Editors

1. For more information please contact Jack Fellows, Communications and Media Manager on or 07825942934

2.  Read the BIA's analysis of party manifestos here:

About the BIA 

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.